Division of Celgene Corp.
Latest From RedoxTherapies Inc.
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Celgene Corp.
- Senior Management
- Michail Sitkovsky, PhD, Founder
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.